コンテンツへスキップ
Merck
  • Polyacrylamide gel 10 years experience: with particular reference to complications from filling of the body of the lip.

Polyacrylamide gel 10 years experience: with particular reference to complications from filling of the body of the lip.

Journal of cosmetic dermatology (2014-11-18)
Adam Rish
要旨

A review of 242 facial treatments, in 86 different patients, with polyacrylamide gel (PAAG) was carried out by the author between 2003 and 2013. To evaluate by retrospective study the long-term outcomes of PAAG filling for facial contouring. To quantify adverse events and patient comfort in prior mixing 0.3 mL of 2% lidocaine/1 mL PAAG and decanting into a smaller volume syringe. Review of clinical records combined with a patient survey. 11 of 166 (6.6%) lip body infections; 1 of 202 (0.5%) in other sites. Addition of 2% lidocaine (55 treatments/28 patients) reduced lip body infections (8.7% to 5.7%, P < 0.05%) and mean pain score (8/10 to 2/10). No patients sustained any long-term side effects and all (even those infected) were eventually satisfied. Seven lip asymmetries, after infected PAAG drainage, were corrected with further PAAG, showing adverse events to be contamination rather than immune reaction. Facial usage of PAAG with lidocaine results in high levels of patient satisfaction and low incidence of side effects (0.5%) except in the lip body (6.6%). Potential users, fearful of complications, may more readily use this cost-effective and long-lasting dermal filler if they avoid injection of the lip body.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リドカイン, powder
USP
リドカイン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
リドカイン, analytical standard
Sigma-Aldrich
テトラカイン, ≥98% (TLC)
Supelco
リドカイン, Pharmaceutical Secondary Standard; Certified Reference Material
リドカイン, European Pharmacopoeia (EP) Reference Standard
プリロカイン, European Pharmacopoeia (EP) Reference Standard